ProBio Accelerates Chimagen’s Global Market Expansion, Paving the Way for Innovative Antibody Therapy
ProBio is proud to support its partner Chengdu Chimagen Biosciences Co., Ltd (Chimagen), in a landmark strategic agreement with pharmaceutical leader GlaxoSmithKline (GSK). This collaboration includes GSK's acquisition of Chimagen's clinical-stage trispecific antibody, CMG1A46, with an initial payment of $300 million and potential milestone payments totaling up to $550 million, contigent upon successful development and commercialization.
ProBio has provided comprehensive preclinical CMC services to support the advancement of this innovative therapy, which represents a major breakthrough in trispecific antibody therapeutics. The CMG1A46 antibody uniquely targets CD3, CD19, and CD20, demonstrating efficacy in the elimination of B cells and showing potential for treating autoimmune diseases such as systemic lupus erythematosus (SLE) and lupus nephritis (LN). Notably, this is the first CD3/CD19/CD20 trispecific antibody to enter clinical trials, exhibiting promise for treating resistant and relapsed B-cell blood cancers.
Dr. Li Chen, CEO of ProBio, shared her enthusiasm: "We congratulate Chimagen on this significant milestone. Our shared vision for multispecific antibody innovation aligns perfectly, and we're excited to accelerate the progress of CMG1A46 to bring more effective therapeutic options to patients worldwide."
This partnership highlights ProBio's expertise in enabling the global development of groundbreaking therapies and reinforces its reputation as a trusted collaborator in the biotech market.
About ProBio Inc
ProBio is a fully integrated global end-to-end contract development and manufacturing organization (CDMO) that focuses on enabling biotech and pharmaceutical companies to accelerate novel drug development and supply for clinical trials through to commercialization. With commitment to quality and innovation, ProBio partners with biotech companies worldwide to accelerate the delivery of advanced therapies to patients in need.
For more information about the expansion and how to collaborate with ProBio, please visit https://www.probiocdmo.com
